These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 23466621)
1. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up. Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483 [TBL] [Abstract][Full Text] [Related]
3. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura. Clausen MR; Segel E; Brandsborg M; d'Amore F Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717 [TBL] [Abstract][Full Text] [Related]
4. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261 [TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292 [TBL] [Abstract][Full Text] [Related]
7. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis. Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715 [TBL] [Abstract][Full Text] [Related]
8. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Jovancevic B; Lindholm C; Pullerits R Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795 [TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura]. Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608 [TBL] [Abstract][Full Text] [Related]
10. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab]. Toubi E Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731 [TBL] [Abstract][Full Text] [Related]
11. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Schweizer C; Reu FJ; Ho AD; Hensel M Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529 [TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J; Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322 [TBL] [Abstract][Full Text] [Related]
13. [Recurrent infections in an ITP patient treated with rituximab]. Rosenberg-Bezalel S; Asher I; Sthoeger Z Harefuah; 2012 Nov; 151(11):617-9, 655. PubMed ID: 23367730 [TBL] [Abstract][Full Text] [Related]
14. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency. Al-Ahmad M; Al-Rasheed M; Al-Muhani A J Investig Allergol Clin Immunol; 2010; 20(3):259-62. PubMed ID: 20635793 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717 [TBL] [Abstract][Full Text] [Related]
16. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA; Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant. Gray C; Kalumba K; Pati N; Peterson A; Connell TG J Pediatr Hematol Oncol; 2013 May; 35(4):e174-7. PubMed ID: 23459375 [TBL] [Abstract][Full Text] [Related]
19. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura]. Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508 [TBL] [Abstract][Full Text] [Related]
20. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]